Following the success in SLNB, this hybrid concept is now increasingly adopted for research in receptor-targeted tracers (e.g., neuroendocrine tumors using Cy5-111In-DTPA-Tyr3-octreotate [156], prostate cancer using PSMA I&F [157] and breast cancer using 111In-DTPA-trastuzumab IRDye800 (Wang2015)). This evidence concerns the gene FOLH1 and prostate carcinoma.